GlassScriptPhysician profile
David Brooks Wilson
NPI 1922030832
$22,222.03
in general payments reported to CMS, 2019-2025
47 companies · $63.99 in 2025
The $63.99 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $4,150 · 2021: $2,796 · 2022: $121 · 2023: $24.10 · 2024: $93.02 · 2025: $63.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11,742.13 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $3,406.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,234.35 | 2019-2022 | |
| Amarin Pharma, INC. | $631.50 | 2019-2021 | |
| Abbvie INC. | $517.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $443.74 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.31 | 2019-2021 | |
| Amgen INC. | $406.87 | 2019-2021 | |
| Abbott Laboratories | $317.32 | 2019-2022 | |
| Novo Nordisk INC | $276.12 | 2019-2022 | |
| Mannkind Corporation | $209.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $185.65 | 2019-2022 | |
| Medtronic Minimed, INC. | $163.39 | 2019-2020 | |
| Clarus Therapeutics INC. | $150.45 | 2020-2021 | |
| Esperion Therapeutics, INC. | $142.67 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.